A Phase 1 Study of MM-141 in Patients With Advanced Solid Tumors

• Status: Completed
• Trial end date: 1969-12-31
• Target enrollment: 0
• Participant gender: All

Summary

This study is a Phase 1 and pharmacologic open-labeled dose-escalation trial using a "3+3" design, evaluating MM-141 at varying dose levels and frequencies.

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Merrimack Pharmaceuticals

Criteria

Inclusion Criteria:

• Advanced malignant solid tumors for which no curative therapy exists that has recurred or pgrogressed following standard therapy

• Eighteen years of age or above

• Able to understand and sign an informed consent (or have a legal representative who is able to do so)

• Measurable disease according to RECIST v1.1

• ECOG Performance Score of 0 or 1

• Adequate bone marrow, hepatic, renal and cardiac function

• Willing to abstain from sexual intercourse or to use an effective form of contraception during the study and for 90 days following the last dose of MM-141

Exclusion Criteria:

• Active infection or fever > 38.5°C during screening visits or on the first scheduled day of dosing

• Symptomatic CNS disease

• Received other recent antitumor therapy

• Pregnant or breast feeding